donepezil has been researched along with Nerve Degeneration in 15 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 5.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| " Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation." | 4.93 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. ( Barrantes, FJ; Peralta, MC; Perez-Lloret, S, 2016) |
| "Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy." | 3.01 | From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. ( Bennett, KA; Bradley, SJ; Broad, LM; Brown, AJH; Brown, GA; Brown, J; Browning, M; Bundgaard, C; Cansfield, JE; Christopoulos, A; Congreve, MS; Cooke, RM; Cross, DM; Dawson, GR; de Graaf, C; Deakin, JFW; Dias, JM; Dwomoh, L; Errey, JC; Goonawardena, AV; Hudson, BD; Hurrell, E; Jazayeri, A; Langmead, CJ; Liptrot, J; Marshall, FH; Mattedi, G; Molloy, C; Morairty, SR; Nathan, PJ; Okrasa, K; Osborne, G; Patel, JC; Perini, F; Phillips, K; Pickworth, M; Robertson, N; Rucktooa, P; Sexton, PM; Shahabi, S; Smith, RT; Tasker, T; Tehan, BG; Teobald, B; Tobin, AB; Vinson, M; Warneck, J; Weir, M, 2021) |
| "Alzheimer's disease is a progressive disorder with the moderate to severe stages generally characterized by significant cognitive, functional, and behavioral dysfunction." | 2.47 | Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. ( Cummings, J; Sabbagh, M, 2011) |
| " The results showed that piperine at all dosage range used in this study significantly improved memory impairment and neurodegeneration in hippocampus." | 1.36 | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. ( Chonpathompikunlert, P; Muchimapura, S; Wattanathorn, J, 2010) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 1.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "Donepezil pretreatment prevented acute glutamate- and ionomycin-induced neurotoxicity, but not S-nitrosocysteine-induced neurotoxicity, suggesting that donepezil protects neurons via nAChR at levels before nitric oxide synthase activation against acute glutamate neurotoxicity." | 1.35 | Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. ( Akaike, A; Fujii, T; Izumi, Y; Kume, T; Niidome, T; Ohgi, Y; Sugimoto, H; Takada-Takatori, Y, 2008) |
| "Donepezil is an acetylcholinesterase inhibitor that is used to treat Alzheimer's disease." | 1.35 | Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. ( Abe, T; Fujiki, M; Hikawa, T; Ishii, K; Kamida, T; Kobayashi, H; Kubo, T; Sugita, K, 2008) |
| "Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low." | 1.33 | Treatment of progressive supranuclear palsy and corticobasal degeneration. ( Lang, AE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, AJH | 1 |
| Bradley, SJ | 1 |
| Marshall, FH | 1 |
| Brown, GA | 1 |
| Bennett, KA | 1 |
| Brown, J | 1 |
| Cansfield, JE | 1 |
| Cross, DM | 1 |
| de Graaf, C | 1 |
| Hudson, BD | 1 |
| Dwomoh, L | 1 |
| Dias, JM | 1 |
| Errey, JC | 1 |
| Hurrell, E | 1 |
| Liptrot, J | 1 |
| Mattedi, G | 1 |
| Molloy, C | 1 |
| Nathan, PJ | 1 |
| Okrasa, K | 1 |
| Osborne, G | 1 |
| Patel, JC | 1 |
| Pickworth, M | 1 |
| Robertson, N | 1 |
| Shahabi, S | 1 |
| Bundgaard, C | 1 |
| Phillips, K | 1 |
| Broad, LM | 1 |
| Goonawardena, AV | 1 |
| Morairty, SR | 1 |
| Browning, M | 1 |
| Perini, F | 1 |
| Dawson, GR | 1 |
| Deakin, JFW | 1 |
| Smith, RT | 1 |
| Sexton, PM | 1 |
| Warneck, J | 1 |
| Vinson, M | 1 |
| Tasker, T | 1 |
| Tehan, BG | 1 |
| Teobald, B | 1 |
| Christopoulos, A | 1 |
| Langmead, CJ | 1 |
| Jazayeri, A | 1 |
| Cooke, RM | 1 |
| Rucktooa, P | 1 |
| Congreve, MS | 1 |
| Weir, M | 1 |
| Tobin, AB | 1 |
| Brewster, JT | 1 |
| Dell'Acqua, S | 1 |
| Thach, DQ | 1 |
| Sessler, JL | 1 |
| Sifringer, M | 1 |
| Bendix, I | 1 |
| von Haefen, C | 1 |
| Endesfelder, S | 1 |
| Kalb, A | 1 |
| Bührer, C | 1 |
| Felderhoff-Mueser, U | 1 |
| Spies, CD | 1 |
| Laursen, B | 1 |
| Mørk, A | 1 |
| Kristiansen, U | 1 |
| Bastlund, JF | 1 |
| Kim, SH | 1 |
| Chung, DK | 1 |
| Lee, YJ | 1 |
| Song, CH | 1 |
| Ku, SK | 1 |
| Perez-Lloret, S | 1 |
| Peralta, MC | 1 |
| Barrantes, FJ | 1 |
| Takada-Takatori, Y | 1 |
| Kume, T | 1 |
| Ohgi, Y | 1 |
| Izumi, Y | 1 |
| Niidome, T | 1 |
| Fujii, T | 1 |
| Sugimoto, H | 1 |
| Akaike, A | 1 |
| Chonpathompikunlert, P | 1 |
| Wattanathorn, J | 1 |
| Muchimapura, S | 1 |
| Wang, L | 1 |
| Harms, MP | 1 |
| Staggs, JM | 1 |
| Xiong, C | 1 |
| Morris, JC | 1 |
| Csernansky, JG | 1 |
| Galvin, JE | 1 |
| Yoshiyama, Y | 1 |
| Kojima, A | 1 |
| Ishikawa, C | 1 |
| Arai, K | 1 |
| Sabbagh, M | 1 |
| Cummings, J | 1 |
| Lang, AE | 1 |
| Ginestet, L | 1 |
| Ferrario, JE | 1 |
| Raisman-Vozari, R | 1 |
| Hirsch, EC | 1 |
| Debeir, T | 1 |
| Gongadze, N | 1 |
| Antelava, N | 1 |
| Kezeli, T | 1 |
| Okudjava, M | 1 |
| Pachkoria, K | 1 |
| Fujiki, M | 1 |
| Kubo, T | 1 |
| Kamida, T | 1 |
| Sugita, K | 1 |
| Hikawa, T | 1 |
| Abe, T | 1 |
| Ishii, K | 1 |
| Kobayashi, H | 1 |
4 reviews available for donepezil and Nerve Degeneration
| Article | Year |
|---|---|
Classics in Chemical Neuroscience: Donepezil.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Humans; Nerv | 2019 |
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Topics: Animals; Cholinergic Agents; Cholinergic Neurons; Clinical Trials as Topic; Cognition Disorders; Dem | 2016 |
Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.
Topics: Acetylcholine; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Clinical Trials as Topic; Delaye | 2011 |
The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Humans; Ind | 2008 |
1 trial available for donepezil and Nerve Degeneration
| Article | Year |
|---|---|
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amino Acid Sequence; Animals; Blood Pressure; CHO | 2021 |
10 other studies available for donepezil and Nerve Degeneration
| Article | Year |
|---|---|
Oxygen toxicity is reduced by acetylcholinesterase inhibition in the developing rat brain.
Topics: Animals; Animals, Newborn; Blotting, Western; Brain; Cholinesterase Inhibitors; Disease Models, Anim | 2013 |
Hippocampal P3-like auditory event-related potentials are disrupted in a rat model of cholinergic degeneration in Alzheimer's disease: reversal by donepezil treatment.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal; Auditory Perception; CA1 Region, Hippocampal; Ch | 2014 |
Neuroprotective effects of Danggui-Jakyak-San on rat stroke model through antioxidant/antiapoptotic pathway.
Topics: Animals; Antioxidants; Apoptosis; Behavior, Animal; Biomarkers; Caspase 3; Cerebral Cortex; Cholines | 2016 |
Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil.
Topics: Animals; Apoptosis; Cells, Cultured; Cerebral Cortex; Cholinesterase Inhibitors; Cytoprotection; Don | 2008 |
Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Aziridines; Benzodioxoles; Choline; Cog | 2010 |
Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Coh | 2010 |
Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Donepezil; Humans; Indans; | 2010 |
Treatment of progressive supranuclear palsy and corticobasal degeneration.
Topics: Amantadine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Donepezil; Dopamine Agents; | 2005 |
Donepezil induces a cholinergic sprouting in basocortical degeneration.
Topics: Acetylcholine; Alzheimer Disease; Animals; Basal Nucleus of Meynert; Cerebral Cortex; Cholinergic Fi | 2007 |
Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury.
Topics: Animals; Brain; Brain Concussion; Brain Injuries; Cholinesterase Inhibitors; Disease Models, Animal; | 2008 |